Developed by NIH, hollow fiber assay (HFA) is an in vivo cancer drug screening platform and considered as an excellent platform bridging the in vitro and xenograft model; with several advantages such as, low cost, shorter test cycle and less animal required. Recently, we developed this unique structure known as the microtube array membrane (MTAM), which consists of a single layer, ultra-thin wall, one-to-one connected fibers which are capable of providing a short diffusion distance and a larger surface area. Potentially this translates to improved reliability, sensitivity and rapidness of the HFA. In our study, we have successfully established a small molecule drug-screening platform via MTAM in HFA. In this proposal, the novelty of the hollow fiber substrate will be explored as monoclonal antibody drug-screening platform HFA substrate. Three main tasks are proposed to verify aforementioned concept: (1) Tumor cells within MTAMs: in vitro cell cultures within the lumen of the MTAMs will be treated with different monoclonal antibodies. The overall inhibition of cancer cells growth for HFA will be defined to determine the best monoclonal antibody drugs. (2) The in vivo cytotoxicity of selected monoclonal antibody against cancer cells within MTAM will be evaluated. (3) The mechanism of monoclonal antibody will be examined and the specific receptor will be determined for the accuracy of treatment. The final goal of this proposal is to develop functional MTAMs as advanced HFA substrates for rapid, low cost, and high fidelity in vivo monoclonal antibody drug screening platform.
|Effective start/end date||11/1/16 → 10/31/17|
- Microtube Array Membrane (MTAM)
- Hollow Fiber Assay (HFA)
- in vivo Anti-cancer Drug Screening Platform
- Monoclonal Antibody